6533b824fe1ef96bd1280a0a

RESEARCH PRODUCT

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

Javier De La SernaPau MontesinosPau MontesinosJose D. González-sanmiguelManuel Pérez-encinasSalut BrunetMarta SobasFlor García-álvarezIsolda FernándezMarcos GonzálezCristina GilJosep-maria RiberaMiguel A. SanzMiguel A. SanzJosé González-camposMonika PaluszewskaCelina BenaventeOlga SalameroMar TormoBob LöwenbergFélix MansoEdo VellengaJordi EsteveRebeca Rodríguez-veigaJuan Bergua

subject

MaleMultivariate analysisOverweightTOXICITYBody Mass Index0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsDIFFERENTIATION SYNDROMEOutcomeAged 80 and overAIDA protocolMercaptopurineMortality rateIncidence (epidemiology)HematologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomeVincristinePopulation Surveillance030220 oncology & carcinogenesisFemalemedicine.symptomUnderweightAdultmedicine.medical_specialtyAdolescentACUTE MYELOID-LEUKEMIADIAGNOSISYoung Adult03 medical and health sciencesInternal medicinemedicineAsparaginaseHumansObesityRisk factorAgedRESPONSE CRITERIAOVERWEIGHTbusiness.industrynutritional and metabolic diseasesANTHRACYCLINEmedicine.diseaseObesityRISK-ADAPTED TREATMENTMethotrexateTRANS-RETINOIC ACIDPrednisonebusinessBody mass index030215 immunology

description

PETHEMA, HOVON, PALG, GATLA cooperative groups.

10.1111/ejh.13346http://hdl.handle.net/10261/234214